News Sentiment

ICCC sentiment intelligence

ImmuCell Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.89 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+5.8% over one week, +12.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Price to earnings forward of ImmuCell Corporation – NASDAQ:ICCC

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction 5.8% Price confirming higher
Trend fit Trend active 12.5% over four weeks
Fair value 94.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 25
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
TradingKey 8
TradingView 4
dars.gov.et 4
The Globe and Mail 4
simplywall.st 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 20
Macro sensitivity 3
Analyst action 2
Deals and strategy 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
The Manila Times Direct company coverage

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Corporation has reported strong preliminary, unaudited sales results for the second quarter and first six months of 2026. The company saw a 11.5% increase in total product sales to $7.2 million in Q2 2026 compared to Q2 2025, primarily driven by a significant 27.7% rise

Tone
Positive 70/100
Event
Earnings
Published
10 Jul 2026 17:09
Source
The Manila Times
Stock Titan Direct company coverage

ImmuCell sales jump 12% in Q2 as U.S. demand lifts calf products

ImmuCell (Nasdaq: ICCC) announced preliminary, unaudited Q2 2026 product sales of $7.2 million, an 11.5% increase year over year, with domestic sales rising 27.7%. For the first half of 2026, total product sales reached $17.5 million, up 20.9% compared to 2025. Strong U.S. demand

Tone
Positive 81/100
Event
Macro sensitivity
Published
09 Jul 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

ImmuCell reports Q2 product sales up 11.5% to $7.2M; six‑month sales up 20.9% to $17.5M

ImmuCell (ICCC) announced preliminary, unaudited product sales for Q2 2026 reached $7.2 million, an 11.5% increase year-over-year, with six-month sales up 20.9% to $17.5 million. The growth was primarily driven by a 27.7% increase in domestic sales, attributed to improved product

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 20:09
Source
TradingView
Stock Titan Direct company coverage

ImmuCell (ICCC) Q2 2026 sales hit $7.2M as six-month revenue climbs 20.9%

ImmuCell Corporation reported preliminary Q2 2026 sales of $7.2 million, an 11.5% increase year-over-year, driven by strong domestic demand, though international sales declined significantly. For the first six months of 2026, total product sales rose 20.9% to $17.5 million. The c

Tone
Positive 71/100
Event
Earnings
Published
09 Jul 2026 20:09
Source
Stock Titan
Feedstuffs Direct company coverage

ImmuCell adds Jacee Lancaster to Commercial Team

ImmuCell Corp. announced the hiring of Jacee Lancaster as sales and marketing manager for its Western region, marking the company's fifth new hire in three months. Lancaster will focus on supporting dairy and beef producers, veterinarians, and distribution partners in understandi

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 14:10
Source
Feedstuffs
Market source Direct company coverage

The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell

This Zacks Analyst Blog highlights research reports for five companies: JPMorgan Chase & Co. (JPM), Novartis AG (NVS), Qualcomm Inc. (QCOM), Genie Energy Ltd. (GNE), and ImmuCell Corp. (ICCC). The report provides insights into each company's recent performance, growth drivers, an

Tone
Positive 71/100
Event
Analyst action
Published
26 Jun 2026 05:26
Source
Market source
Investing.com Direct company coverage

ImmuCell CEO buys $75,960 in common stock

ImmuCell Corp's CEO, Paul Francis Olivier te Boekhorst, recently acquired 8,000 shares of common stock for $75,960. This purchase follows a significant 60.85% jump in the company's shares over the past six months and a strong first quarter in 2026, marking the first time ImmuCell

Tone
Positive 74/100
Event
Earnings
Published
22 Jun 2026 13:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 ImmuCell Corporation For: 22 June By Investing.com

This article reports on a Form 4 filing for ImmuCell Corporation on June 22. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be filed by company insiders when they trade shares of their own company's stock. The article

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 13:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy

ImmuCell CEO Paul Francis Olivier te Boekhorst has increased his direct holdings in the company by purchasing 8,000 shares of common stock at $9.495 per share. This open-market transaction, filed on June 18, 2026, brings his total direct ownership to 17,785 shares. The purchase s

Tone
Positive 75/100
Event
Deals and strategy
Published
22 Jun 2026 12:10
Source
Stock Titan
The Globe and Mail Direct company coverage

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

ImmuCell Corporation (ICCC) shares are trading at a premium valuation compared to the industry average, but the article argues that this is justified due to the company's strong operational progress, market-share gains, and long-term growth prospects. Key factors include improved

Tone
Positive 75/100
Event
Market update
Published
19 Jun 2026 09:09
Source
The Globe and Mail
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of ImmuCell Corp's (ICCC) shareholder structure, listing major individual and institutional holders. It also presents a historical view of institutional shareholding over several quarters and details recent shareholder activity, includin

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for ImmuCell Corp (ICCC), highlighting its business segments and regional contributions. The data, updated on April 6, 2026, shows that the First Defense® product line accounts for the vast majority of revenue at 99.29%, with the

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 05:44
Source
TradingKey
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ImmuCell Corp's (ICCC) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page also displays current stock information for ICCC,

Tone
Neutral 50/100
Event
Capital return
Published
19 Jun 2026 05:09
Source
TradingKey
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for ImmuCell Corp (ICCC), noting its current valuation score of 8.62, which ranks it 76th out of 157 in the Pharmaceuticals industry. The P/E ratio is reported at -153.81, showing a significant deviation from recent highs and lows. Key v

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:44
Source
TradingKey
Investing.com Direct company coverage

ImmuCell shareholders approve director elections and key proposals at annual meeting

ImmuCell Corporation (NASDAQ:ICCC) shareholders approved the election of seven directors and several key proposals at their 2026 Annual Meeting. Over 81% of eligible shares were represented, and proposals included executive compensation, the 2025 Stock Option and Incentive Plan,

Tone
Positive 73/100
Event
Market update
Published
17 Jun 2026 19:11
Source
Investing.com
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for ImmuCell Corp (ICCC), noting its current score of 2.85, ranking 113 out of 157 in the Pharmaceuticals industry. It highlights the company's beta of 0.54, indicating its stock tends to underperform in up-markets but experiences smaller d

Tone
Neutral 50/100
Event
Analyst action
Published
16 Jun 2026 19:10
Source
TradingKey
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of ImmuCell Corp (ICCC), covering its price momentum score, support and resistance levels, and various technical indicators and moving averages. The current price momentum score for ICCC is 6.44, and the stock is trading between a resist

Tone
Negative 39/100
Event
Market update
Published
16 Jun 2026 19:10
Source
TradingKey
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for ImmuCell Corp (ICCC), stating that no earnings forecast score is currently available for the company. It notes that the Pharmaceuticals industry average score is 7.84. The article also mentions that relevant data for financial forecas

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 12:40
Source
TradingKey
TradingKey Direct company coverage

ImmuCell Corp (ICCC) Institutional Confidence

ImmuCell Corp (ICCC) has an institutional shareholding score of 3.00, placing it 94th in the Pharmaceuticals industry. Institutional investors hold 23.86% of the company's shares, an increase of 17.57% quarter-over-quarter. James Simons is the largest institutional shareholder, h

Tone
Positive 60/100
Event
Market update
Published
16 Jun 2026 07:11
Source
TradingKey